can glp 1 cause kidney stones GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes GLP-1 Receptor Agonists and Diabetic
Description
The additional GIP receptor activity in tirzepatide does not appear to add thyroid risk, as GIP receptors are not significantly expressed on human thyroid C-cells
The Hype vs
Track your tirzepatide injection dates and any dose changes
Copycat products and inadequate oversight: We already have a troubling market of compounded products, research peptides, microdosing plans, longevity packages, and cosmetic weight-loss programs with inadequate medical supervision
The new sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are potential game changers for people with type 2 diabetes
